LYW-105
/ LyncBio Therapeutics (Shanghai) Co., Ltd
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 18, 2026
LYW-105: A novel bispecific antibody-drug conjugate with enhanced antitumor efficacy and broader therapeutic index
(AACR 2026)
- "In summary, LYW-105 has been thoroughly compared to benchmark single-target ADCs in preclinical settings. It demonstrated potent cytotoxicity in vitro and significant antitumor activity in vivo across various tumor cell lines, showcasing a broader therapeutic index than benchmark ADCs."
ADC • Bispecific • Clinical • Oncology • Solid Tumor
1 to 1
Of
1
Go to page
1